Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.30 USD
-0.09 (-1.67%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Aurinia Pharmaceuticals Inc [AUPH]
Reports for Purchase
Showing records 21 - 40 ( 138 total )
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
A Reset of Expectations to a Slower Growth Trajectory; Reduce PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Aurinia Well-Positioned in Bench Strength Following Management Departures; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
EU Approval of LUPKYNIS Brings First Oral Option for LN in Europe and Triggers a $30M Milestone Payment; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
2Q Recap: 2022 LUPKYNIS Revenue Guidance Maintained, Though PT Adjusted to $26 on Moderation in Growth Trajectory
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Positive CHMP Opinion for LUPKYNIS in the EU to Lead to Additional Revenue Stream, Further Supporting U.S. Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Model Update to Preview 1Q22 Results; Adjust PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
4Q21 Recap: We and Consensus Got Ahead of Ourselves; Creating Strong Entry Point; Affirm Buy, Reduce PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
AURORA 2-3-Year Safety Results- As Good as it Gets Without a Biopsy.
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
AURORA 2 Data Demonstrate Safety And Efficacy of Long-Term LUPKYNIS Treatment For LN; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Aurinia Pharmaceuticals Inc
Industry: Medical - Drugs
3Q21 Recap; LUPKYNIS Growth Remains on Track; EU Approval Expected in 3Q22; Raise PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E